vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and FIRST COMMUNITY CORP (FCCO). Click either name above to swap in a different company.
FIRST COMMUNITY CORP is the larger business by last-quarter revenue ($23.2M vs $16.1M, roughly 1.4× Journey Medical Corp). FIRST COMMUNITY CORP runs the higher net margin — 23.7% vs -7.8%, a 31.5% gap on every dollar of revenue. Over the past eight quarters, FIRST COMMUNITY CORP's revenue compounded faster (19.1% CAGR vs 11.0%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
United Community is an American bank. United is one of the largest full-service financial institutions in the Southeast, with $27.7 billion in assets and 200 offices in Alabama, Florida, Georgia, North Carolina, South Carolina and Tennessee. In addition to its presence in the Southeast, United Community is the largest bank headquartered in South Carolina by total asset size.
DERM vs FCCO — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $23.2M |
| Net Profit | $-1.2M | $5.5M |
| Gross Margin | — | — |
| Operating Margin | -2.8% | — |
| Net Margin | -7.8% | 23.7% |
| Revenue YoY | 27.3% | — |
| Net Profit YoY | -182.0% | 37.6% |
| EPS (diluted) | $-0.04 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $23.2M | ||
| Q4 25 | $16.1M | $20.6M | ||
| Q3 25 | $17.0M | $20.5M | ||
| Q2 25 | $15.0M | $19.5M | ||
| Q1 25 | $13.1M | $18.4M | ||
| Q4 24 | $12.6M | $17.5M | ||
| Q3 24 | $14.6M | $17.0M | ||
| Q2 24 | $14.9M | $16.3M |
| Q1 26 | — | $5.5M | ||
| Q4 25 | $-1.2M | — | ||
| Q3 25 | $-2.3M | $5.2M | ||
| Q2 25 | $-3.8M | $5.2M | ||
| Q1 25 | $-4.1M | $4.0M | ||
| Q4 24 | $1.5M | — | ||
| Q3 24 | $-2.4M | $3.9M | ||
| Q2 24 | $-3.4M | $3.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | -2.8% | — | ||
| Q3 25 | -9.0% | 32.2% | ||
| Q2 25 | -19.2% | 34.2% | ||
| Q1 25 | -25.3% | 28.2% | ||
| Q4 24 | 17.7% | 30.9% | ||
| Q3 24 | -19.8% | 29.5% | ||
| Q2 24 | -19.7% | 24.7% |
| Q1 26 | — | 23.7% | ||
| Q4 25 | -7.8% | — | ||
| Q3 25 | -13.6% | 25.4% | ||
| Q2 25 | -25.3% | 26.6% | ||
| Q1 25 | -31.0% | 21.8% | ||
| Q4 24 | 12.1% | — | ||
| Q3 24 | -16.3% | 22.7% | ||
| Q2 24 | -22.6% | 20.0% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.04 | $0.62 | ||
| Q3 25 | $-0.09 | $0.67 | ||
| Q2 25 | $-0.16 | $0.67 | ||
| Q1 25 | $-0.18 | $0.51 | ||
| Q4 24 | $0.10 | $0.55 | ||
| Q3 24 | $-0.12 | $0.50 | ||
| Q2 24 | $-0.17 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | — |
| Total DebtLower is stronger | $25.3M | — |
| Stockholders' EquityBook value | $31.9M | $220.8M |
| Total Assets | $94.6M | $2.4B |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $24.1M | — | ||
| Q3 25 | $24.9M | — | ||
| Q2 25 | $20.3M | — | ||
| Q1 25 | $21.1M | — | ||
| Q4 24 | $20.3M | — | ||
| Q3 24 | $22.5M | — | ||
| Q2 24 | $23.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — |
| Q1 26 | — | $220.8M | ||
| Q4 25 | $31.9M | $167.6M | ||
| Q3 25 | $25.9M | $161.6M | ||
| Q2 25 | $19.2M | $155.5M | ||
| Q1 25 | $21.5M | $150.0M | ||
| Q4 24 | $20.1M | $144.5M | ||
| Q3 24 | $10.9M | $143.3M | ||
| Q2 24 | $11.3M | $136.2M |
| Q1 26 | — | $2.4B | ||
| Q4 25 | $94.6M | $2.1B | ||
| Q3 25 | $85.2M | $2.1B | ||
| Q2 25 | $81.2M | $2.0B | ||
| Q1 25 | $85.0M | $2.0B | ||
| Q4 24 | $80.2M | $2.0B | ||
| Q3 24 | $64.0M | $1.9B | ||
| Q2 24 | $65.2M | $1.9B |
| Q1 26 | — | — | ||
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-6.3M | $18.7M | ||
| Q3 25 | $-2.4M | $9.2M | ||
| Q2 25 | $-942.0K | $-236.0K | ||
| Q1 25 | $-2.8M | $6.4M | ||
| Q4 24 | $2.2M | $11.6M | ||
| Q3 24 | $-1.2M | $10.8M | ||
| Q2 24 | $-5.2M | $-292.0K |
| Q1 26 | — | — | ||
| Q4 25 | — | $17.6M | ||
| Q3 25 | — | $9.0M | ||
| Q2 25 | — | $-454.0K | ||
| Q1 25 | — | $6.2M | ||
| Q4 24 | — | $10.5M | ||
| Q3 24 | — | $10.6M | ||
| Q2 24 | — | $-634.0K |
| Q1 26 | — | — | ||
| Q4 25 | — | 85.3% | ||
| Q3 25 | — | 44.2% | ||
| Q2 25 | — | -2.3% | ||
| Q1 25 | — | 34.0% | ||
| Q4 24 | — | 60.3% | ||
| Q3 24 | — | 62.5% | ||
| Q2 24 | — | -3.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 5.4% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 6.3% | ||
| Q3 24 | — | 1.1% | ||
| Q2 24 | — | 2.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.77× | ||
| Q2 25 | — | -0.05× | ||
| Q1 25 | — | 1.61× | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | 2.80× | ||
| Q2 24 | — | -0.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
FCCO
| Net Interest Income | $18.4M | 79% |
| Noninterest Income | $4.8M | 21% |
